Corrigendum re “Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non–muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study” (European Urology (2012) 62(5) (797–802), (S0302283812006082) (10.1016/j.eururo.2012.05.032));Neoadjuvant short-term intensive intravesical Mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: Preliminary results of a randomised phase 2 study

European Urology

Volumn 62, Issue 5, 2012, Pages 797-802

  Colombo, Renzo ^a   Rocchini, Lorenzo ^a   Suardi, Nazareno ^a   Benigni, Fabio ^a   Colciago, Giorgia ^a   Bettiga, Arianna ^a   Pellucchi, Federico ^a   MacCagnano, Carmen ^a   Briganti, Alberto ^a   Salonia, Andrea ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Intravesical chemotherapy; Mitomycin C; Neoadjuvant chemotherapy bladder; Non muscle invasive urothelial carcinoma

Indexed keywords

MITOMYCIN C;

ADULT; AGED; ALLERGY; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYSTITIS; CYSTOSCOPY; DERMATITIS; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NON MUSCLE INVASIVE BLADDER CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT RESPONSE; URINE INCONTINENCE;

EID: 84867081302     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2018.09.012     Document Type: Erratum

References (24)

1. M. Maffezzini, F. Campodonico, G. Canepa, G. Capponi, and V. Fontana Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder Eur Urol 51 2007 956 961
2. R.J. Popert, J. Goodall, M.J. Coptcoat, P.M. Thompson, M.K. Parmar, and J.R. Masters Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin Br J Urol 74 1994 195 199
3. A.G. van der Heijden, P.M. Moonen, and E.B. Cornel Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response J Urol 176 2006 1349 1353
4. A.P. van der Meijden, R.R. Hall, K.H. Kurth, C. Bouffioux, and R. Sylvester Phase II trials in Ta, T1 bladder cancer. The marker tumour concept Br J Urol 77 1996 634 637
5. F. Calais da Silva, L. Denis, A. Bono, C. Bollack, and C. Bouffioux Intravesical chemoresection with 4′-epi-doxorubicin in patients with superficial bladder tumors Eur Urol 14 1988 207 209
6. J.T. Dalton, M.G. Wientjes, R.A. Badalament, J.R. Drago, and J.L. Au Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients Cancer Res 51 1991 5144 5152
7. A.Y. Elliott, P. Cleveland, and J. Cervenka Characterization of a cell line from human transitional cell cancer of the urinary tract J Natl Cancer Inst 53 1974 1341 1349
8. C. Fujiyama, A. Jones, S. Fuggle, R. Bicknell, D. Cranston, and A.L. Harris Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion Br J Cancer 84 2001 558 564
9. L. Hu, M.G. Wientjes, J. Li, and J.L. Au Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs AAPS J 12 2010 586 591
10. G.S. Oshinsky, Y. Chen, T. Jarrett, A.E. Anderson, and G.H. Weiss A model of bladder tumor xenografts in the nude rat J Urol 154 1995 1925 1929
11. A. Trotti, A.D. Colevas, and A. Setser CTCAE: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181
12. C. Jenkinson, A. Coulter, and L. Wright Short form 36 (SF36) health survey questionnaire: normative data for adults of working age BMJ 306 1993 1437 1440
13. E. Pasin, D.Y. Josephson, A.P. Mitra, R.J. Cote, and J.P. Stein Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history Rev Urol 10 2008 31 43
14. E. Solsona, I. Iborra, J.V. Ricos, J.L. Monrós, J. Casanova, and R. Dumont Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup J Urol 161 1999 1120 1123
15. S. Gudjónsson, L. Adell, and F. Merdasa Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study Eur Urol 55 2009 773 780
16. S.M. Di Stasi, M. Valenti, and C. Verri Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial Lancet Oncol 12 2011 871 879
17. A.V. Bono, R.R. Hall, and L. Denis Chemoresection in Ta-T1 bladder cancer Eur Urol 29 1996 385 390
18. P. Gontero, G. Casetta, and G. Maso Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC) Eur Urol 46 2004 339 343
19. K. Hendricksen, A.G. van der Heijden, and E.B. Cornel Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer World J Urol 27 2009 337 342
20. R.T. Divrik, U. Yildirim, F. Zorlu, and H. Ozen The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial J Urol 175 2006 1641 1644
21. H.W. Herr, S.M. Donat, and V.E. Reuter Management of low grade papillary bladder tumors J Urol 178 2007 1201 1205
22. R.S. Pruthi, N. Baldwin, V. Bhalani, and E.M. Wallen Conservative management of low risk superficial bladder tumors J Urol 179 2008 87 90
23. M.S. Soloway, D.S. Bruck, and S.S. Kim Expectant management of small, recurrent, noninvasive papillary bladder tumors J Urol 170 2003 438 441
24. M. Racioppi, A. Volpe, and E. Cappa Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach Urol Int 85 2010 266 269